$ONC News

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $436

BeOne Highlights Cancer Drug Results at Major Oncology Conference

Insider Selling: Corsee Corazon Sanders Unloads $65K Of BeOne Medicines Stock

Insider Decision: Margaret Dugan Offloads $65K Worth Of BeOne Medicines Stock

Sell Alert: Alessandro Riva Cashes Out $65K In BeOne Medicines Stock

BeOne Medicines Publishes Data From HERIZON-GEA-01 In The New England Journal Of Medicine, To Present Oral Presentation At American Society Of Clinical Oncology On June 1

BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative

Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today

BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $425

Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $420

Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $409

Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $413

BeOne Medicines AG 2026 Q1 - Results - Earnings Call Presentation

BeOne Medicines Raises FY2026 Sales Guidance from $6.200B-$6.400B to $6.300B-$6.500B vs $6.369B Est.

BeiGene Q1 Adj. EPS $3.24 Beats $0.79 Estimate, Sales $1.513B Beat $1.441B Estimate.

FDA Grants Priority Review To BeOne Medicines' Supplemental Biologics License Application For Tevimbra (Tislelizumab) In Combination With Ziihera (Zanidatamab) And Chemotherapy For Untreated Unresectable Locally Advanced/Metastatic HER2-positive Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma

BeOne Medicines shares are trading higher after Wolfe Research initiated coverage on the stock with an Outperform rating and announced a $340 price target.

BeOne Medicines shares are trading higher after Wolfe Research initiated coverage on the stock with an Outperform rating and announced a $340 price target.

Wolfe Research Initiates Coverage On BeOne Medicines with Outperform Rating, Announces Price Target of $340